Zacks Investment Research upgraded shares of Biosig Technologies (OTCMKTS:BSGM) from a hold rating to a buy rating in a research note released on Friday. They currently have $1.50 price target on the stock.

According to Zacks, “BioSig Technologies, Inc. is a medical device company which is engaged in developing technology platform to improve cardiac recording during electrophysiology studies and ablation procedures. “

Separately, Chardan Capital reaffirmed a buy rating on shares of Biosig Technologies in a report on Sunday, October 1st.

Shares of Biosig Technologies (OTCMKTS BSGM) opened at $1.41 on Friday. Biosig Technologies has a fifty-two week low of $1.20 and a fifty-two week high of $2.00.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://theolympiareport.com/2017/12/05/biosig-technologies-bsgm-upgraded-by-zacks-investment-research-to-buy.html.

Biosig Technologies Company Profile

BioSig Technologies, Inc is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System.

Get a free copy of the Zacks research report on Biosig Technologies (BSGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biosig Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.